Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COMMENTARY
COMMENTARY
- A Happy Year 2006 to Japanese Pharmaceutical Stocks!
January 23, 2006
- Industry Should Insist on Brand Average Market Price Principle
January 16, 2006
- The Bottom of the Tornado
January 16, 2006
- <New Year's commentary>Looking at the Pharma Industry Backward from 2009 -1- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
- <New Year's commentary>Looking at the Pharma Industry Backward from 2009 -2- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
- Schrodinger's Cat
December 12, 2005
- Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
- Importance of Framing
November 21, 2005
- A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
- A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
- Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
- COMMENTARY 2 articles
October 10, 2005
- COMMENTARY 6 articles
September 19, 2005
- Where Will the Japanese Pharmaceutical Industry Drift? - From "The Sky Is the Limit" to the Abyss -
August 29, 2005
- COMMENTARY 5 articles
August 8, 2005
- 2 Rosai Hospitals Start Prescriptions by the Generic Name
July 25, 2005
- COMMENTARY 6 articles
July 25, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
- Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…